Cerus Corporation (CERS)

NGM – Real vaqt narxi. Valyuta: USD

2.55

+0.03 (1.19%)

Yopilishda: May 12, 2026, 4:00 PM EDT

2.54

-0.01 (-0.39%)

Bozordan keyin: May 12, 2026, 7:58 PM EDT

10.05.2026

Cerus Corporation: Strong Q1 Results Validate The Turnaround Thesis

Cerus' Q1 2026 product revenues grew another 24% YoY. This was mainly thanks to strong platelet demand and rapid IFC adoption. Management raised its 2026 product revenue guidance to $227-$231 million, which would imply promising 10%-12% YoY growth. IFC volumes rose about 120% YoY, making it the clearest current growth vertical beyond platelets.

01.05.2026

Cerus Corporation (CERS) Q1 2026 Earnings Call Transcript

27.04.2026

Cerus Corporation Announces New, Four-Year Supply Agreement with French Blood Establishment for INTERCEPT Blood System

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today the signing of a new, four-year supply agreement with Établissement Français du Sang (EFS), the French Blood Establishment, for the INTERCEPT Blood System. The agreement covers the INTERCEPT Blood System for platelets and plasma as well as the next generation, LED-based INT200 illumination device. “We are proud to announce a new four-year supply agreement with the French Blood Establishment,” said Christian Boute.

16.04.2026

Cerus Corporation to Release First Quarter 2026 Financial Results on April 30, 2026

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its first quarter 2026 financial results will be released on Thursday, April 30, 2026, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the.

16.03.2026

Cerus Appoints Vivek Jayaraman as President and Chief Executive Officer

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced that Vivek Jayaraman, Cerus' chief operating officer, will be promoted to president and chief executive officer, effective July 1, 2026. William “Obi” Greenman will become executive chairman of the board of directors. At the time of his appointment, Mr. Jayaraman will join the Board of Directors. “Following a thorough succession planning process, this transition represents a natural step as we prepare for the nex.

05.03.2026

Cerus's Record 2025 Sets It Up For Another Leg Higher

CERS' INTERCEPT platform (kits + illuminators) is scaling globally, with record 2025 results. They've also grown their adoption across ~40 countries. INT200 received European approval and launched. They also have a US PMA filing targeted for 2026. This means CERS may soon have another hardware refresh cycle, with future kit pull-through.

02.03.2026

Cerus Corporation (CERS) Q4 2025 Earnings Call Transcript

Videolar

No Data

There is no data to display

Press-relizlar

27.04.2026

Cerus Corporation Announces New, Four-Year Supply Agreement with French Blood Establishment for INTERCEPT Blood System

16.03.2026

Cerus Appoints Vivek Jayaraman as President and Chief Executive Officer

02.03.2026

Cerus Corporation Announces Full-Year and Fourth Quarter 2025 Financial Results

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today financial results for its full year and fourth quarter ended December 31, 2025. “Our strong 2025 results reflect our disciplined execution, as we continued to deliver on our mission of safeguarding the world's blood supply. This past year, we achieved our highest annual kit shipments, enabling an estimated 600,000 patients worldwide to receive INTERCEPT-treated blood components,” said William “Obi” Greenman, Ceru.

20.02.2026

Cerus Corporation to Participate in the TD Cowen 46th Annual Health Care Conference

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that members of the Company's management are scheduled to present at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, at 10:30 a.m. EST. A live webcast of the fireside chat will be accessible through the Investor Relations page of the Cerus website at http://www.cerus.com/ir. A replay will be available for 90 days after the event. ABOUT CERUS Cerus Corporation is dedicated solely to safe.

Cerus Corporation (CERS)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Cerus Corporation (CERS)

Cerus Corporation: Strong Q1 Results Validate The Turnaround Thesis

Cerus Corporation (CERS) Q1 2026 Earnings Call Transcript

Cerus Corporation Announces New, Four-Year Supply Agreement with French Blood Establishment for INTERCEPT Blood System

Cerus Corporation to Release First Quarter 2026 Financial Results on April 30, 2026

Cerus Appoints Vivek Jayaraman as President and Chief Executive Officer

Cerus's Record 2025 Sets It Up For Another Leg Higher

Cerus Corporation (CERS) Q4 2025 Earnings Call Transcript

Videolar

No Data

Press-relizlar

Cerus Corporation Announces New, Four-Year Supply Agreement with French Blood Establishment for INTERCEPT Blood System

Cerus Appoints Vivek Jayaraman as President and Chief Executive Officer

Cerus Corporation Announces Full-Year and Fourth Quarter 2025 Financial Results

Cerus Corporation to Participate in the TD Cowen 46th Annual Health Care Conference

Cerus Corporation: Strong Q1 Results Validate The Turnaround Thesis

Cerus Corporation (CERS) Q1 2026 Earnings Call Transcript

Cerus Corporation Announces New, Four-Year Supply Agreement with French Blood Establishment for INTERCEPT Blood System

Cerus Corporation to Release First Quarter 2026 Financial Results on April 30, 2026

Cerus Appoints Vivek Jayaraman as President and Chief Executive Officer

Cerus's Record 2025 Sets It Up For Another Leg Higher

Cerus Corporation (CERS) Q4 2025 Earnings Call Transcript

Videolar

No Data

Press-relizlar

Cerus Corporation Announces New, Four-Year Supply Agreement with French Blood Establishment for INTERCEPT Blood System

Cerus Appoints Vivek Jayaraman as President and Chief Executive Officer

Cerus Corporation Announces Full-Year and Fourth Quarter 2025 Financial Results

Cerus Corporation to Participate in the TD Cowen 46th Annual Health Care Conference

Search stocks

Cerus Corporation (CERS)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Cerus Corporation (CERS)

Cerus Corporation: Strong Q1 Results Validate The Turnaround Thesis

Cerus Corporation (CERS) Q1 2026 Earnings Call Transcript

Cerus Corporation Announces New, Four-Year Supply Agreement with French Blood Establishment for INTERCEPT Blood System

Cerus Corporation to Release First Quarter 2026 Financial Results on April 30, 2026

Cerus Appoints Vivek Jayaraman as President and Chief Executive Officer

Cerus's Record 2025 Sets It Up For Another Leg Higher

Cerus Corporation (CERS) Q4 2025 Earnings Call Transcript

Videolar

No Data

Press-relizlar

Cerus Corporation Announces New, Four-Year Supply Agreement with French Blood Establishment for INTERCEPT Blood System

Cerus Appoints Vivek Jayaraman as President and Chief Executive Officer

Cerus Corporation Announces Full-Year and Fourth Quarter 2025 Financial Results

Cerus Corporation to Participate in the TD Cowen 46th Annual Health Care Conference

Cerus Corporation: Strong Q1 Results Validate The Turnaround Thesis

Cerus Corporation (CERS) Q1 2026 Earnings Call Transcript

Cerus Corporation Announces New, Four-Year Supply Agreement with French Blood Establishment for INTERCEPT Blood System

Cerus Corporation to Release First Quarter 2026 Financial Results on April 30, 2026

Cerus Appoints Vivek Jayaraman as President and Chief Executive Officer

Cerus's Record 2025 Sets It Up For Another Leg Higher

Cerus Corporation (CERS) Q4 2025 Earnings Call Transcript

Videolar

No Data

Press-relizlar

Cerus Corporation Announces New, Four-Year Supply Agreement with French Blood Establishment for INTERCEPT Blood System

Cerus Appoints Vivek Jayaraman as President and Chief Executive Officer

Cerus Corporation Announces Full-Year and Fourth Quarter 2025 Financial Results

Cerus Corporation to Participate in the TD Cowen 46th Annual Health Care Conference